News

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

As of July 13, 2026, a meeting date has not been set.

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

The FDA issued a nationwide recall of a steroid eye drop.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her session on the hormonal and aesthetic considerations ODs should make when treating these patients.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for Vizz in Australia and New Zealand.

Ping Moore, OD, outlines modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Jade Coats, OD, FAAO, details what has changed in dry eye treatment in the last decade, and how to optimize the ocular surface through the power of comanagement.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

Justin Schweitzer, OD, FAAO, details how to distinguish secondary glaucomas from primary glaucomas in a recent presentation.

Jessica Steen, OD, FAAO, DipABO, weighs in on what the optometric community should know concerning what side effects their patients may experience.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.

Host Hamza Shah, OD, MS, FAAO, is joined by Brianna Rhue, OD, FAAO, to discuss eye care terminology, inspired by Zhang et al's paper, "Myopia Progression Management: Current Trends and Future Directions."

An overview of the diagnosis and evidence-based management of one of the most common causes of visual acuity reduction following intraocular surgery.

In a preference study, Karl Csaky, MD, PhD and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

Jessilin Quint, OD, MBA, FAAO, said that integrating AI into your practice can start small.

A large real-world cohort study by Takashi Nishida, MD, PhD et al finds OSA is associated with elevated glaucoma risk.

According to the survey, one in five sufferers reported that dry eye symptoms affect their self-confidence (22%) and emotional wellbeing (20%).

Shareen M. Greenbaum, MD, and Amanda Amberg, OD, recognize comanagement as an opportunity to target dry eye early and use advanced diagnostics and treatments for healthier ocular surfaces.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, details what she finds concerning and surprising in a recent study she conducted with Kaleb Abbott, OD, MS, FAAO, FOWNS.

In this podcast, retina specialist John Kitchens, MD, has a conversation with a patient about the choice he made for anti-VEGF therapy to reduce his treatment burden, then discusses recent clinical trial data on therapeutic options with extended treatment intervals.

Kaleb Abbott, OD, MS, FAAO, FOWNS, details one of his lectures during AOA's Optometry's Meeting 2026.

Jacqueline Theis, OD, FAAO, gave tips to clinicians on how to critically read studies in order to assess if they are applicable to their everyday practice.

Denise Whittam, OD, said that the Acuvue Oasys lens family holds her go-to lenses for patients for their comfortability.

Kaleb Abbott, OD, MS, FAAO, FOWNS, outlined a recent study he conducted with Neda Gioia OD, CNS, IFMCP, FOWNS, on optometry and burnout – in addition to unpublished data on job satisfaction.